A5076368199- Blood groups and transfusion
- Erythrocyte Function and Pathophysiology
- Blood disorders and treatments
- Acute Myeloid Leukemia Research
- Platelet Disorders and Treatments
- Hemoglobinopathies and Related Disorders
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Complement system in diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Hematological disorders and diagnostics
- Renal Diseases and Glomerulopathies
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Neonatal Health and Biochemistry
- Adenosine and Purinergic Signaling
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Multiple Myeloma Research and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Parvovirus B19 Infection Studies
- Blood properties and coagulation
- Childhood Cancer Survivors' Quality of Life
University of Milan
2016-2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2016-2025
European Institute of Oncology
2022-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2024
Ospedale Maggiore
2012-2024
IRCCS Policlinico San Donato
2023
European School of Oncology
2023
King's College Hospital
2019-2021
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2018
Abstract We explored the impact of luspatercept therapy on overall survival (OS) and possible predictors response in low‐risk (LR) myelodysplastic syndrome (MDS) patients. evaluated 331 anemic patients treated with luspatercept. Hematological (HI) was defined as (i) hemoglobin (Hb) increase ≥1.5 g/dL nontransfusion‐dependent (NTD) patients, (ii) red blood cell (RBC) transfusion independence (TI) a concomitant Hb g/dL, or RBC‐TI without an 1.5 >50% reduction RBC burden (TB) for TD Response...
Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there no consensus on optimal treatment. Daratumumab, monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasma cells and thus autoantibody secretion. In addition, because CD38 also expressed activated T cells, daratumumab may act via immunomodulatory effects. We evaluated the efficacy safety monotherapy in an international retrospective study...
Abstract Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH) treatment. The anti‐C5 monoclonal antibody eculizumab was first treatment to improve hemolysis, thrombotic risk, and survival in PNH although at price a life‐long intravenous fortnightly drug. Additionally, suboptimal response may occur up 2/3 patients with persistent anemia due incomplete control intravascular development upstream C3‐mediated extravascular hemolysis (EVH), or concomitant bone marrow...
ABSTRACT We retrospectively analyzed a large international cohort of 1113 patients with aplastic anemia to evaluate treatment choice and outcome in elderly as compared younger population. Overall, 319 (29%) were > 60 years old at diagnosis (60–64 ( n = 85), 106 65–69 106), 128 70 128)). Elderly showed more severe thrombocytopenia onset significantly lower overall response (complete plus partial) first‐line therapy 6 months (47% vs. 65%, p < 0.0001), irrespective modality (ATG or CyA...
Abstract Objectives To evaluate the efficacy of a salvage treatment with rituximab (RTX) in adults primary immune thrombocytopenia (ITP), terms short‐term response and long‐term (LTR, i.e., probability to achieve maintain response) identify biological clinical predictors response. Methods We retrospectively evaluated outcome patients ITP treated standard dosage RTX (375 mg/m 2 × 4) as therapy five Italian centers. One hundred three patients, median age 46 yr, were included. The period...
Abstract In this large single-centre study, we report high prevalence (25%) of, small (<10%) and very (<1%), paroxysmal nocturnal hemoglobinuria (PNH) clones by high-sensitive cytometry among 3085 patients tested. Given PNH association with bone marrow failures, analyzed 869 myelodysplastic syndromes (MDS) 531 aplastic anemia (AA) within the cohort. were more frequent larger in AA vs. MDS ( p = 0.04). clone, irrespective of size, was a good predictor response to immunosuppressive...
Introduction Autoimmune hemolytic anemia (AIHA) is classified according to the direct antiglobulin test (DAT) and thermal characteristics of autoantibody into warm cold forms, in primary versus secondary depending on presence associated conditions.Areas covered AIHA displays a multifactorial pathogenesis, including genetic (association with congenital conditions certain mutations), environmental (drugs, infections, SARS-CoV-2, pollution, etc.), miscellaneous factors (solid/hematologic...